Back

Withdrawal of neurohumoral blockade in patients with normalized ejection fractions after cardiac resynchronization therapy: long-term follow-up of the STOP-CRT trial

18 May 2025 (14:00 - 14:45)
Organised by: Logo
Congress Presentation Part of: Diuretics and intravenous iron and more Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Mr Marnicq Van Es

Genk (Belgium)

2 More presentations in this session

Presentation thumbnail
Medical treatment implementation in ambulatory patients with HF: preliminary data from the nationwide BRING-UP3 HF study
Doctor E. D'Elia (Bergamo, IT)
Abstract Slides Video
Presentation thumbnail
Effects of intravenous IRON supplementation in Heart Failure with Preserved Ejection Fraction (IRON-HFpEF): a comprehensive multicenter phase 2 randomized clinical trial
Mr S. Nassiri (Amsterdam, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Diuretics and intravenous iron and more

The Event

Event poster

Heart Failure 2025

18 May 2025 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Long-term outcome in non-progressors to cardiac resynchronization therapy
thumbnail
Congress Presentation
WITHDRAWal of Heart Failure Pharmacotherapy in Patients with Normalized Left Ventricular Function After AF Rhythm Control in Arrhythmia Induced Cardiomyopathy-The WITHDRAW-AF Randomized Clinical Trial
thumbnail
Congress Presentation
Long-term follow-up of the TRED-HF trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources